• Home
  • About Us
  • Technology
  • Pipeline
  • Team
  • Partnerships
  • Media
  • Publications
  • Contact Us
HDT Bio

Bioprocess Online Live: Why The Cancer Vaccine Concept Is En Vogue Again

Feb 13, 2024 | In the News

Click here to view...

Bioprocess Online: Why The Cancer Vaccine Concept Is En Vogue Again

Feb 13, 2024 | In the News

Click here to view...

Law360: Indian Pharma Co. Can’t Get Fees In $950M COVID Vax Suit

Feb 13, 2024 | In the News

Click here to view...

Bioprocess Online Live: Where Therapeutic Cancer Vaccines Go Next

Feb 13, 2024 | In the News

Click here to view...

Bioprocess Online: Where Therapeutic Cancer Vaccines Go Next

Feb 13, 2024 | In the News

Click here to view...

Bioprocess Online Live: Navigating Cancer Vaccines’ Regulatory Waters

Feb 13, 2024 | In the News

Click here to view...
« Older Entries
Next Entries »

Recent Posts

  • MalarVx licenses HDT Bio’s repRNA/LION™ Technology for Novel Malaria Vaccine
  • Science Direct: Some assembly required: a single-RNA vaccine against enterovirus-D68
  • Fierce Biotech: NIH establishes pandemic preparedness network, plans up to $100M in yearly funding for work on new treatments and vaccines
  • HDT Bio to Help Spearhead RNA Vaccine Development in National Pandemic Preparedness Initiative
  • HDT Bio Publishes Peer-Reviewed Article Describing the Development of an RNA Vaccine to Prevent Infection and Disease Caused by Enterovirus D68

Recent Comments

No comments to show.

Privacy Policy

Terms of Use

©2024 HDT Bio

  • Follow
  • Follow